Houston, TX, United States of America

Vax-Immune, LLC

Calculating rank
USPTO Granted Patents = 5


Trademarks = 3

Forward Citations = 10

Loading Chart...
Loading Chart...

6 inventors (with patents filed for the assignee):

goldMedal Bhairavi Parikh (3 out of 13 patents)

silverMedal James Stone (2 out of 24 patents)

bronzeMedal Mika Nenonen (2 out of 4 patents)

4.  Adrienne McNees (2 out of 2 patents)

5.  Philip Michael Weiner (2 out of 2 patents)

6.  Leonard E Weisman (2 out of 2 patents)


5 patents:

Company Overview
Vax-immune, LLC is an innovative biotechnology firm specializing in the development of advanced vaccines and immunotherapeutics. The company focuses on harnessing cutting-edge research to create novel solutions for infectious diseases and immune-related disorders. With a dedicated team of scientists and researchers, Vax-immune is committed to improving global health through its pioneering technologies and collaborations with leading health organizations. The company's pipeline includes potential breakthroughs in vaccine efficacy and delivery mechanisms, aiming to address both emerging and endemic health challenges. Vax-immune strives to contribute significantly to public health by providing effective immunological interventions tailored to diverse populations.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

5 Patents

#845 in Houston, TX

#3,337 in Texas

#51,708 in US

Houston, TX (US)
Houston, TX, United States of America
Forward Citations = 10

6 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vax-Immune, LLC. Retrieved from https://idiyas.com/company/vax-immune

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…